Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GNG2 | P59768 | 1/20 | 0.39 |
| ▸ | GNB1 | P62873 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6252203 | 0.79 | PDE4D (0.46) | ACHE | |
| SCHEMBL8352739 | 0.77 | CYP1A2 (0.56) | ATMTDP1LMNAPOLBACHE | |
| SCHEMBL13626344 | 0.75 | TUBB4A (0.40) | ATMTDP1LMNAPOLBACHE | |
| SCHEMBL27394377 | 0.71 | ADRA1A (0.55) | ACHEDRD1CYP1A2 | |
| SCHEMBL27390763 | 0.71 | ALDH1A1 (0.49) | TDP1ACHE | |
| SCHEMBL29368136 | 0.71 | DRD2 (0.60) | ATM | |
| SCHEMBL9037155 | 0.67 | CHRM2 (0.53) | — | |
| SCHEMBL22409978 | 0.67 | ATM (0.70) | ATMTDP1POLBACHEGNG2 | |
| SCHEMBL28949968 | 0.66 | CA1 (0.51) | DRD1 | |
| SCHEMBL8319207 | 0.66 | ATM (0.43) | ATMTDP1LMNAPOLBACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291998-A1 | EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291998-A1 | EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF | PSMC4, PSMB6, EPOR | ATM 3227/4885TDP1 4482/4885LMNA 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.